Tema ETF Trust | ||||||||
Tema Cardiovascular and Metabolic ETF | ||||||||
Schedule of Investments | ||||||||
November 30, 2023 (Unaudited) | ||||||||
Investments | Number of Shares | Value | ||||||
COMMON STOCKS - 98.1% | ||||||||
Biotechnology - 49.1% | ||||||||
Akero Therapeutics, Inc.* | 6,204 | $ | 103,855 | |||||
Alnylam Pharmaceuticals, Inc.* | 2,303 | 387,480 | ||||||
Amgen, Inc. | 2,162 | 582,962 | ||||||
Arcturus Therapeutics Holdings, Inc.* | 6,675 | 159,800 | ||||||
Arrowhead Pharmaceuticals, Inc.* | 9,024 | 191,309 | ||||||
Ascendis Pharma A/S - ADR*^ | 2,914 | 292,653 | ||||||
Bridgebio Pharma, Inc.* | 14,101 | 404,840 | ||||||
Crinetics Pharmaceuticals, Inc.* | 10,387 | 330,203 | ||||||
Cytokinetics, Inc.* | 5,499 | 184,107 | ||||||
Intellia Therapeutics, Inc.* | 12,832 | 380,212 | ||||||
Ionis Pharmaceuticals, Inc.* | 6,862 | 339,463 | ||||||
Madrigal Pharmaceuticals, Inc.* | 1,458 | 296,411 | ||||||
Mereo Biopharma Group plc - ADR*^ | 122,952 | 256,970 | ||||||
Mineralys Therapeutics, Inc.* | 18,471 | 123,017 | ||||||
Mirum Pharmaceuticals, Inc.* | 5,734 | 183,889 | ||||||
Rocket Pharmaceuticals, Inc.* | 15,040 | 350,883 | ||||||
Tenaya Therapeutics, Inc.* | 47,893 | 90,039 | ||||||
Ultragenyx Pharmaceutical, Inc.* | 8,319 | 323,193 | ||||||
Vertex Pharmaceuticals, Inc.* | 1,739 | 617,015 | ||||||
Verve Therapeutics, Inc.* | 10,623 | 119,827 | ||||||
Viking Therapeutics, Inc.* | 15,652 | 191,267 | ||||||
Zealand Pharma A/S*^ | 5,076 | 249,032 | ||||||
6,158,427 | ||||||||
Health Care Equipment & Supplies - 22.8% | ||||||||
Boston Scientific Corp.* | 5,452 | 304,712 | ||||||
Dexcom, Inc.* | 4,372 | 505,053 | ||||||
Edwards Lifesciences Corp.* | 4,982 | 337,331 | ||||||
Inari Medical, Inc.* | 4,700 | 280,543 | ||||||
Insulet Corp.* | 1,928 | 364,566 | ||||||
Masimo Corp.* | 2,303 | 215,929 | ||||||
Medtronic plc - ADR ^ | 5,264 | 417,277 | ||||||
Omnicell, Inc.* | 6,674 | 222,645 | ||||||
Shockwave Medical, Inc.* | 1,222 | 213,300 | ||||||
2,861,356 | ||||||||
Insurance - 1.2% | ||||||||
Oscar Health, Inc., Class A * | 17,249 | 146,617 | ||||||
Life Sciences Tools & Services - 2.1% | ||||||||
West Pharmaceutical Services, Inc. | 753 | 264,122 | ||||||
Pharmaceuticals - 22.9% | ||||||||
Bayer AG^ | 6,956 | 237,444 | ||||||
Bristol-Myers Squibb Co. | 5,828 | 287,787 | ||||||
Chugai Pharmaceutical Co., Ltd.^ | 12,267 | 431,736 | ||||||
Cymabay Therapeutics, Inc.* | 11,703 | 223,878 | ||||||
Eli Lilly & Co. | 1,034 | 611,135 | ||||||
Novartis AG^ | 3,713 | 360,912 | ||||||
Novo Nordisk A/S, Class B^ | 6,157 | 625,261 | ||||||
Structure Therapeutics, Inc. - ADR*^ | 1,598 | 88,993 | ||||||
2,867,146 | ||||||||
TOTAL COMMON STOCKS (Cost $12,262,446) | 12,297,668 | |||||||
SHORT-TERM INVESTMENTS - 0.4% | ||||||||
Money Market Funds | ||||||||
First American Treausry Obligations Fund - Class X, 5.277% (a) | 49,876 | 49,876 | ||||||
TOTAL MONEY MARKET FUNDS (Cost $49,876) | 49,876 | |||||||
TOTAL INVESTMENTS (Cost $12,312,322) - 98.5% | 12,347,544 | |||||||
OTHER ASSETS LESS LIABILITIES - 1.5% | 187,497 | |||||||
NET ASSETS - 100.0% | $ | 12,535,041 |
* Non-income producing security. | |||||
^ Foreign security. | |||||
(a) 7-day net yield. | |||||
ADR - American Depositary Receipt | |||||
plc - Public Limited Company | |||||
The Global Industry Classification Standard (GICS®) was developed by and/or is the exclusive property of MSCI, Inc. and Standard & Poor Financial Services LLC (“S&P”). GICS is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. |
Tema Cardiovascular and Metabolic ETF | ||
November 30, 2023 (Unaudited) | ||
ALLOCATION BY SECTOR | ||
Sector | Percentage of Total Net Assets | |
Health Care | 96.9% | |
Financials | 1.2% | |
Money Market Fund and Other Assets and Liabilities | 1.9% | |
Total | 100.0% |
ALLOCATION BY COUNTRY | ||
Country | Percentage of Total Net Assets | |
United States | 74.9% | |
Denmark | 9.3% | |
Japan | 3.4% | |
Ireland | 3.3% | |
Switzerland | 2.9% | |
United Kingdom | 2.1% | |
Germany | 1.9% | |
Cayman Islands | 0.7% | |
Other(1) | 1.5% | |
Total | 100.0% | |
(1) Includes cash and net other assets (liabilities). |
Tema ETF Trust | |||||||
Tema Cardiovascular and Metabolic ETF | |||||||
Notes to Quarterly Schedule of Investments | |||||||
November 30, 2023 (Unaudited) | |||||||
Investment Valuation | |||||||
The Fund discloses the fair value of their investments in a hierarchy that distinguishes between: (1) market participant assumptions developed based on market data obtained from sources independent of the Fund's (observable inputs) and (2) the Fund's’ own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows: | |||||||
• Level 1 — Quoted prices in active markets for identical assets that the Fund's have the ability to access. | |||||||
• Level 2 — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). | |||||||
• Level 3 — Significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments). | |||||||
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. | |||||||
The following is a summary of the inputs used to value the Fund's investments as of November 30, 2023: |
Tema Cardiovascular and Metabolic ETF | Level 1 | Level 2 | Level 3 | Total | ||||||||||||
Investments | ||||||||||||||||
Common Stocks * | $ | 12,297,668 | $ | - | $ | - | $ | 12,297,668 | ||||||||
Money Market Fund | 49,876 | - | - | 49,876 | ||||||||||||
Total Investments | $ | 12,347,544 | $ | - | $ | - | $ | 12,347,544 | ||||||||
* See Schedule of Investments for segregation by industry. |